The European Medicines Agency (EMA) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months. The Veterinary Medicines Directorate (VMD) the authority responsible for veterinary medicines in the UK, has previously approved the extension of the shelves life for Strangvac.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.175 SEK | +3.34% | +0.85% | -34.04% |
Mar. 04 | Intervacc AB Announces Changes in the Nomination Committee | CI |
Feb. 28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.04% | 28.84M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IVACC Stock
- News Intervacc AB
- The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months